TLDR
- Xenon Pharmaceuticals stock jumped 40% after its Phase 3 X-TOLE2 study of azetukalner hit its primary endpoint in both dose groups.
- The 25 mg dose cut monthly focal onset seizure frequency by 53.2% from baseline, vs. 10.4% for placebo.
- Results outperformed the earlier Phase 2b X-TOLE study, which showed a 34.6% placebo-adjusted median percent change.
- Over half of patients on the 25 mg dose (54.8%) saw at least a 50% reduction in seizure frequency.
- Xenon plans to file a New Drug Application (NDA) with the FDA in Q3 2026.
Xenon Pharmaceuticals (XENE) stock surged 40% on Monday after the company announced that its Phase 3 X-TOLE2 study of azetukalner met its primary endpoint in focal onset seizures. The results came in stronger than expected, sending the stock sharply higher at the open.
Xenon Pharmaceuticals Inc., XENE
The trial enrolled 380 adults with highly treatment-resistant epilepsy. Participants had tried a median of five prior antiseizure medications and were still experiencing around 12.75 seizures per month at baseline.
The 25 mg dose of azetukalner produced a median percent change of -53.2% in monthly focal onset seizure frequency from baseline. The placebo group saw just -10.4%. That puts the placebo-adjusted difference at -42.7%.
𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐍𝐞𝐰𝐬: Xenon is up this morning on its release of data for Azetukalner in Focal Onset Seizures (FOS). $XENE pic.twitter.com/VVgvbhJl78
— BiotechTV (@BiotechTV) March 9, 2026
That number matters. The earlier Phase 2b X-TOLE study had shown a placebo-adjusted median percent change of -34.6% in the 25 mg group. X-TOLE2 cleared that bar by a wide margin.
The 15 mg dose also performed well, hitting -34.5% median percent change vs. placebo, though the 25 mg results drew the most attention.
Secondary Endpoints Also Hit
The trial also met its key secondary endpoint. In the 25 mg group, 54.8% of participants achieved at least a 50% reduction in monthly seizure frequency — known as the Responder Rate 50. That compared to just 20.8% in the placebo group. The 15 mg group came in at 37.6%.
Of the 332 participants who completed the double-blind period, 322 moved on to the open-label extension study.
The safety profile held up. The most common side effects were dizziness, headache, somnolence, and fatigue. Treatment discontinuation due to adverse events was 14.5% in the 25 mg group, 4.8% in the 15 mg group, and 3.2% in the placebo group.
Xenon CEO Ian Mortimer said the results showed “the highest placebo-adjusted efficacy ever observed in a pivotal epilepsy study,” according to the company’s press release.
What Comes Next
Xenon plans to submit an NDA to the FDA for azetukalner in focal onset seizures in Q3 2026. If approved, it would be the first KV7 potassium channel opener on the market for epilepsy.
Stifel analysts noted the results could push investors to revise upward their peak sales and peak penetration estimates for the drug.
Azetukalner also carries some practical advantages over existing options — once-daily dosing, no titration needed, and no meaningful drug-drug interactions.
The X-TOLE2 data will be presented at an oral session during the American Academy of Neurology (AAN) Annual Meeting in April.
Xenon is also developing azetukalner for depression, though that program was not part of Monday’s announcement.
The stock was trading up around 40% as of Monday morning, with the move driven entirely by the Phase 3 data readout.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
